Evogene Ltd. (NASDAQ: EVGN) is 26.60% higher on its value in year-to-date trading and has touched a low of $0.75 and a high of $6.49 in the current 52-week trading range. The EVGN stock was last observed hovering at around $5.95 in the last trading session, with the day’s gains setting it 0.47% off its average median price target of $9.00 for the next 12 months. It is also 28.67% off the consensus price target high of $9.00 offered by 1 analysts, but current levels are 28.67% higher than the price target low of $9.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $6.42, the stock is 35.03% and 68.50% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing 7.90% at the moment leaves the stock 182.46% off its SMA200. EVGN registered 250.56% gain for a year compared to 6-month gain of 461.32%. The firm has a 50-day simple moving average (SMA 50) of $4.37 and a 200-day simple moving average (SMA200) of $2.79.
The stock witnessed a 50.25% loss in the last 1 month and extending the period to 3 months gives it a 56.58%, and is 15.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.80% over the week and 13.58% over the month.
Evogene Ltd. (EVGN) has around 143 employees, a market worth around $211.67M and $0.81M in sales. Distance from 52-week low is 756.00% and -1.08% from its 52-week high.
Evogene Ltd. (EVGN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Evogene Ltd. (EVGN) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Evogene Ltd. is expected to release its quarterly report on 06/01/2021 and quarterly earnings per share for the current quarter are estimated at $0..
Evogene Ltd. (EVGN) Top Institutional Holders
21 institutions hold shares in Evogene Ltd. (EVGN), with 5.73M shares held by insiders accounting for 18.12% while institutional investors hold 29.21% of the company’s shares. The shares outstanding are 35.58M, and float is at 25.96M with Short Float at 2.24%. Institutions hold 23.92% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 4.62 million shares valued at $18.29 million. The investor’s holdings represent 12.98% of the EVGN Shares outstanding. As of Sep 29, 2020, the second largest holder is Waddell & Reed Financial Inc. with 2.76 million shares valued at $10.92 million to account for 7.75% of the shares outstanding. The other top investors are Senvest Management LLC which holds 0.62 million shares representing 1.73% and valued at over $2.44 million, while UBS Group AG holds 0.36% of the shares totaling 0.13 million with a market value of $0.51 million.
Evogene Ltd. (EVGN): Who are the competitors?
The company’s main competitors (and peers) include 22nd Century Group Inc. (XXII) that is trading 176.70% up over the past 12 months. Short interest in the company’s stock has risen 62.05% from the last report on Nov 29, 2020 to stand at a total of 0.37 million short shares sold with a short interest ratio of 0.46.